It was supposed to be retail week, but Moderna and inflation stole the show.

Monday 🛢️: Rising crude, climbing long-term yields, and megacap tech weakness turned the session into a broad risk-off retreat. Semiconductors and AI infrastructure offered the counterpunch as SanDisk extended its rally and Duos unveiled more than $500M in hosting orders. Nike’s 12-year low and Fabrinet’s after-hours reversal showed how little patience remained when expectations cracked.

Tuesday 🧯: Long-dated yields and a 5% chip selloff pushed stocks into a defensive crouch. Home Depot’s beat could not calm growth worries, while Amylyx’s Phase 3 win and Klarna’s guidance wipeout split the company-news board between feast and famine. Defensives held the line, but rates near their highest since 2007 kept the market’s inflation headache fully funded.

Wednesday 🧬: A personalized cancer-vaccine breakthrough powered health care and carried the S&P 500 above 7,700 while technology slipped. Moderna’s 177% surge, Merck’s record, and the biotech sympathy rally gave retail a rare fundamental moonshot to chase. Target and Estée Lauder strengthened the consumer side, but hawkish Fed minutes kept rate risk alive.

Thursday 🛒: Rising Treasury yields and Walmart’s soft U.S. sales turned a retail warning into a broad risk-off close. Defensive stocks offered little shelter as health care and consumer names absorbed the heaviest selling. Marvell, Cipher, and Bitcoin kept a speculative pocket alive, but the bond market retained the final word.

Friday 🪙: Stocks rebounded broadly even as long-term Treasury yields climbed, with Bitcoin and materials doing most of the risk-on shouting. Robinhood led crypto proxies higher, Tesla shrugged off China’s 2.98M-vehicle recall, and critical-minerals stocks caught fire. Alibaba supplied the counterweight, tumbling as 45% cloud growth collided with a much larger AI bill.

🤩 This week's Stocktwits Top 25 showed how momentum movers fared vs. the indexes.

Here are the closing prices: 

If you’re searching for your next trade idea or want a faster way to research stocks, IBD Digital puts powerful investing tools at your fingertips.

Upgrade your toolkit with access to:
* Smarter Trade Ideas: IBD’s exclusive stock lists leverage advanced algorithms to sort through thousands of stocks and surface the top trade ideas.
* Proprietary Ratings and Tools: With the IBD Stock Checkup® and precise 1-99 ratings, our tools make it easy for DIY investors to trade like professionals.
* Unmatched Market Insights: Read the IBD Market Team’s analysis to find out whether it’s a good time to make new buys or trim your portfolio exposure level.

For a limited time, choose 1 year of IBD Digital for $160 (save $219), or get 2 months for just $12 (save over $65).

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Need a concise summary of what's going on this week? Look no further. Here’s a rundown of this week’s earnings and economic data.

Above is a quick summary. Check out the full Stocktwits earnings calendar for the other names reporting this week.

In addition to the above, check out this week's complete list of economic releases.

🆘 Democratic House leader Jeffries meets with Jared Kushner as midterms loom

⚠ Inside Coca-Cola’s secretive innovation labs:

🧓 Trump reshuffled his portfolio in June, selling names like Meta and buying Berkshire Hathaway

🪴 How the US government pushed the national debt to $40 trillion in less than a generation

📆 Nvidia earnings and Jackson Hole: What to watch this week

🌎 Iran warns Middle East neighbors against joining US ‘economic war’

🤖 Michael Burry Stays Skeptical Of Alibaba After $10.2B AI Share Sale: ‘Issuing Shares Is Now Its New Paradigm’

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋